Small Molecules

14 Feb 2018 GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
14 Feb 2018 Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease
14 Feb 2018 GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta
13 Feb 2018 Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment
13 Feb 2018 Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease
13 Feb 2018 MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer
13 Feb 2018 Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage
13 Feb 2018 Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
13 Feb 2018 Icon Bioscience Receives FDA Approval for DEXYCU™, a Potentially Transformational Drug Therapy for Treating Inflammation Associated with Cataract Surgery
13 Feb 2018 Applied Therapeutics Initiates Phase 1 Trial for AT-001 In Diabetic Complications
13 Feb 2018 Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
13 Feb 2018 FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene
13 Feb 2018 Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer
12 Feb 2018 U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
12 Feb 2018 U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib
12 Feb 2018 AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
09 Feb 2018 Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
09 Feb 2018 Janssen Submits Marketing Authorisation Application for Apalutamide to Treat Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
09 Feb 2018 Vyera Pharmaceuticals Has Initiated a Phase 1 Study of a New Dihydrofolate Reductase Inhibitor Designed as a Potential Treatment for Toxoplasmosis
09 Feb 2018 ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
09 Feb 2018 Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials
08 Feb 2018 ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
08 Feb 2018 Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
08 Feb 2018 Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed
08 Feb 2018 Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing